United Kingdom

People: Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

4:35pm BST
Change (% chg)

1.00 (+0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Preston, Heather 

Dr. Heather Preston is Independent Non-Executive Director of the company. She is currently a Partner and Managing Director of TPG Biotech where she focuses on biotechnology venture capital investing. Prior to joining TPG Biotech in May 2005, she invested with J.P. Morgan Partners and New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a member of the pharmaceutical and medical products consulting practice. She advised large pharmaceutical and biotechnology companies on critical strategic issues such as R&D portfolio prioritisation, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr. Preston currently serves on the Board of Directors of Albireo, Inc (NASDAQ; ALBO), Alder BioPharmaceuticals (NASDAQ; ALDR) and Otonomy, Inc (NASDAQ; OTIC) and several private companies. She previously served on the Boards of Aptalis Pharma (acquired by Forest Labs in 2014), Elevation Pharmaceuticals (acquired by Sunovion in 2012) and was responsible for overseeing TPG Biotech's investment in Par Pharmaceuticals, prior to its acquisition by Endo Pharmaceuticals in 2015. Dr. Preston has an undergraduate degree in Biochemistry from the University of London and a medical degree from the University of Oxford. Dr Preston completed a post-doctoral fellowship in Molecular Biology at the Dana Farber Cancer Institute, Harvard University, and trained in Internal Medicine at the Massachusetts General Hospital and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.

Basic Compensation

Total Annual Compensation, GBP 52,000
Restricted Stock Award, GBP --
Long-Term Incentive Plans, GBP --
All Other, GBP --
Fiscal Year Total, GBP 52,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --